Yes, immunohistochemistry for ER should be performed on this low-grade DCIS
For a 54-year-old woman with low-grade ductal carcinoma in situ, estrogen receptor (ER) testing by immunohistochemistry is necessary to guide decisions about adjuvant endocrine therapy. Progesterone receptor (PR) testing is optional, and HER2 testing is not routinely indicated for pure DCIS.
Rationale for ER Testing
The 2020 ASCO/CAP guidelines explicitly recommend ER testing in DCIS to guide discussions about adjuvant endocrine therapy 1. This represents an evolution from the 2010 position when the evidence was insufficient. The recommendation is now based on:
- NSABP B-24 trial data showing tamoxifen significantly reduced the relative risk of subsequent breast cancer in ER-positive DCIS patients (hazard ratio 0.49, p=0.001) at 10-year follow-up 1
- Additional phase III trial data demonstrating tamoxifen reduced new DCIS or invasive breast cancer incidence (HR 0.48) in ER-positive disease 1
The 2024 NCCN guidelines reinforce that ER testing should be used to determine candidacy for endocrine therapies, with patients showing 1-100% ER staining considered ER-positive and eligible for treatment 2.
Why This Matters for Your Patient
Low-grade DCIS is typically ER-positive (research shows essentially 100% ER positivity in low-grade DCIS) 3, making endocrine therapy highly relevant. Given that:
- She is 54 years old (likely perimenopausal/postmenopausal)
- She has two daughters in their 20s (family considerations for risk reduction)
- Low-grade DCIS carries risk of ipsilateral recurrence and rare but documented risk of invasive recurrence and even metastatic disease 3
Knowing her ER status will directly inform whether she should receive adjuvant tamoxifen or an aromatase inhibitor (if postmenopausal) to reduce her recurrence risk by approximately 50%.
What About PR and HER2?
PR testing is optional in DCIS 1. While it may be performed, it does not add independent predictive or prognostic value beyond ER alone. In the NSABP B-24 trial, ER alone was more predictive than combined ER/PR status for tamoxifen benefit 1.
HER2 testing is not routinely recommended for pure DCIS in standard guidelines 1. While HER2 may be overexpressed in some DCIS cases (particularly comedo-type), there is currently no HER2-targeted therapy approved or routinely used for DCIS management. HER2 testing would only be relevant if invasion is found on final pathology.
Common Pitfall to Avoid
Do not assume that because this is "low-grade" DCIS, it can be managed without biomarker testing. The grade tells you about nuclear features, but ER status is what determines eligibility for the single most effective adjuvant therapy available for DCIS - endocrine therapy that can cut recurrence risk in half 1.